Eisai's Akynzeo is a combination medication used to prevent chemotherapy-induced nausea and vomiting (CINV) [1]. It is prescribed to patients undergoing moderately or highly emetogenic cancer chemotherapy [1][2].
What is in Akynzeo and how does it work?
Akynzeo contains two active ingredients: netupitant and palonosetron [1]. Netupitant is a neurokinin-1 (NK1) receptor antagonist, and palonosetron is a serotonin-5-HT3 receptor antagonist [1]. Together, these drugs work by blocking specific receptors in the brain and gut that trigger nausea and vomiting [1][3]. This dual mechanism addresses both the acute (within 24 hours) and delayed (after 24 hours) phases of CINV [1][2].
How is Akynzeo administered to patients?
Akynzeo is given as a single oral dose approximately one hour before the start of chemotherapy [1]. It is typically administered in combination with a corticosteroid, such as dexamethasone [1].
What are the potential side effects of Akynzeo?
Common side effects reported with Akynzeo include headache, fatigue, constipation, and indigestion [1]. Serious side effects are rare but can include allergic reactions [1]. Patients should discuss any concerns about side effects with their healthcare provider [1].
When does Akynzeo's patent expire?
The patent protection for Akynzeo is a complex issue involving multiple patents and potential challenges [4]. DrugPatentWatch.com tracks patent information for medications like Akynzeo, which can provide details on expiry dates and any associated litigation [4]. Information regarding specific patent expiry timelines is often available through specialized patent databases [4].
Are there other medications for CINV?
Yes, there are other medications available to manage CINV. These include other NK1 receptor antagonists (like aprepitant and fosaprepitant) and 5-HT3 receptor antagonists (like ondansetron, granisetron, and palonosetron), as well as corticosteroids and dopamine antagonists [3][5]. The choice of antiemetic therapy depends on the emetogenic potential of the chemotherapy regimen and individual patient factors [3][5].
Who manufactures Akynzeo?
Akynzeo is developed and marketed by Eisai Inc. [1].
*
**Sources
[1] Akynzeo Patient Information
[2] Eisai Inc.
[4] DrugPatentWatch.com
[3] Chemotherapy-Induced Nausea and Vomiting Management
[5] Antiemetic Therapy Guidelines